6 not yet recruiting, 5 recruiting, 5 unknown, 4 active not recruiting. 12 Phase 2, 3 Not applicable, 3 Phase 1, 3 Phase 3.
Follow SBRT: new trials by email Literature Review of SBRT trials Research Report on SBRT
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Consolidative Stereotactic Radiotherapy for Oligo-Residual Advanced EGFR-Mutant NSCLC After First-Line Third-Generation EGFR-TKI Plus Chemotherapy Third-generation EGFR tyrosine kinase inhibitor, Platinum plus pemetrexed chemotherapy, Pemetrexed maintenance therapy - EGFR-mutant Non-small Cell Lung Cancer, SBRT | Phase 2 | Not yet recruiting | Fudan University | 374 | 2026-10-01 | 2026-09-16 |
| RIsk aDapted Stereotactic Radiotherapy vs. standarD of Care Radiotherapy in Patients With Prostate Cancer in the Adjuvant or saLvage sEtting With or Without Lymph Node Irradiation (RIDDLELN) - A Phase III Trial Stereotactic body radiotherapy (SBRT) to the prostate bed, Standard-of-care radiotherapy (SOC) to the prostate bed - Prostate Cancer (Post Prostatectomy), Prostate Cancer | Phase 3 | Not yet recruiting | Robert Förster | 206 | 2026-09-01 | 2026-09-21 |
| ADC and SBRT for Recurrent/Metastatic Salivary Gland Carcinoma Becotatug Vedotin, SBRT, Becotatug Vedotin or Sacituzumab Tirumotecan - Adenoid Cystic Carcinoma of the Head and Neck, SBRT | Phase 2 | Not yet recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 40 | 2026-05-01 | 2026-05-12 |
| Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy Benmelstobart, SBRT, Anlotinib - Hepatocellular Carcinoma (HCC), First-line Targeted Therapy Failure | Phase 2 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 29 | 2026-04-20 | 2026-04-17 |
| Pelvic Ultra-Hypofractionated Adjuvant Radiotherapy for Endometrial Cancer (PURE-cohort) Ultra-hypofractionation schedule of 27.5Gy in 5 fractions on image-guided adjuvant pelvic IMRT/VMAT radiotherapy - SBRT, Radiation Therapy | Not applicable | Recruiting | Instituto de Investigación Sanitaria Aragón | 50 | 2026-03-30 | 2026-08-25 |
| Single-Fraction Pulmonary Ablative Radiotherapy Outcomes and Quality-of-life Workup Oligometastatic Lung Tumor, NSCLC (Non-small Cell Lung Cancer) | Recruiting | Institut du Cancer de Montpellier - Val d'Aurelle | 190 | 2026-01-14 | 2026-03-02 | |
| SENECA: First Line metaStatic pancrEatic caNcer Primary and Distant (if Oligometastatic) lEsion direCted rAdiotherapy SBRT or RT on primary pancreatic and/or metastatic distant lesions before chemotherapy, Standard systemic therapy (chemotherapy) without RT/SBRT - Radiation Therapy, SBRT | Phase 3 | Active not recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 108 | 2025-01-10 | 2025-04-27 |
| SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma adbelimumab, SBRT, apatinib - Hepatocellular Carcinoma, SBRT | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 80 | 2025-01-01 | 2024-08-06 |
| Efficacy and Safety of a Third-Course of Neoadjuvant Immunochemotherapy Combined With SBRT in Locally Advanced Head and Neck Squamous Cell Carcinoma Patients With Stable Disease After Two Treatment Courses: A Single-Arm Exploratory Study SBRT - SBRT, Neoadjuvant Immunochemotherapy | Not applicable | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 20 | 2024-12-24 | 2024-12-09 |
| SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy SBRT combined with Nimotuzumab followed by Tislelizumab - Nasopharyngeal Cancinoma (NPC), SBRT | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 20 | 2024-11-05 | 2025-07-01 |
| A Phase I Dose-escalation Trial of Definitive Single Dose Stereotactic Body Radiotherapy in Low-risk Breast Cancer Patients: DESERT I Trial SBRT level I, SBRT level II, SBRT level III - Breast Cancer Early Stage Breast Cancer (Stage 1-3), SBRT | Phase 1 | Enrolling by invitation | Universitat de les Illes Balears | 15 | 2024-09-27 | 2024-11-04 |
| Sequential TACE-SBRT Combined With Targeted Immunotherapy for Patients With Intermediate to Advanced Liver Cancer HCC - Hepatocellular Carcinoma, SBRT | Active not recruiting | Nanfang Hospital, Southern Medical University | 17 | 2024-09-01 | 2025-11-17 | |
| SBRT Followed by Neoadjuvant Chemoimmunotherapy of Sindilizumab Plus Docetaxel and Cisplatin for Locoregionally Advanced Squamous Carcinoma of Oral Cavity and Oropharynx SBRT+chemoimmunotherapy - SBRT | Phase 2 | Recruiting | Sun Yat-sen University | 25 | 2023-12-07 | 2024-03-12 |
| Stereotactic Body Radiotherapy (SBRT) for Medically Inoperable Localised Renal Tumors (SABINA Trial) SBRT - Kidney Neoplasm, Renal Cancer | Active not recruiting | Consorci Sanitari de Terrassa | 60 | 2023-03-01 | 2024-05-10 | |
| Observational Study on Extreme Hypofractionation for Localized Prostate Cancer SBRT - Prostate Cancer, Radiotherapy | Recruiting | Universitaire Ziekenhuizen KU Leuven | 246 | 2022-04-25 | 2025-03-30 | |
| Lung Perfusion PET / CT Using Ga68-MAA for Preservation of Lung Function During Stereotactic Pulmonary Radiation Therapy Pre-therapeutic imaging test - SBRT, Non-small Cell Lung Cancer | Phase 2 / Phase 3 | Unknown | University Hospital, Brest | 60 | 2021-07-15 | 2022-09-19 |
| Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer Drug GC4711, Placebo - SBRT, Borderline Resectable Pancreatic Cancer | Phase 2 | Terminated | Galera Therapeutics, Inc. | 177 | 2021-05-07 | 2024-05-21 |
| Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC GC4711 +SBRT, Placebo +SBRT - SBRT, NSCLC | Phase 1 / Phase 2 | Terminated | Galera Therapeutics, Inc. | 47 | 2020-10-18 | 2024-04-30 |
| Combination of Hyperfractionated Radiotherapy With Immunotherapy in Massive Tumors camrelizumab+hyperfractionated radiotherapy - Immunotherapy, SBRT | Unknown | Peking University First Hospital | 60 | 2020-10-15 | 2020-10-14 | |
| Combination of Sintilimab and Stereotactic Body Radiotherapy in Advanced Metastatic HCC Stereotactic body radiation therapy, Anti-PD-1 antibody drug named Sintilimab - Stage IV HCC, Immunotherapy | Phase 2 | Unknown | West China Hospital | 84 | 2020-07-01 | 2020-09-14 |
Showing 20 of 24. Sign in to see all of them.
Carcinoma, Hepatocellular (3) · Carcinoma, Non-Small-Cell Lung (3) · Prostatic Neoplasms (3) · Lung Neoplasms (2) · Breast Neoplasms (1) · Endometrial Neoplasms (1) · Kidney Neoplasms (1) · Mouth Neoplasms (1) · Oropharyngeal Neoplasms (1) · Pancreatic Neoplasms (1)
Neoplasms (14) · Neoplasms by Site (14) · Urogenital Diseases (5) · Urogenital Neoplasms (5) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Genital Diseases (4) · Male Urogenital Diseases (4) · Adenocarcinoma (3) · Bronchial Neoplasms (3) · Carcinoma (3) · Carcinoma, Bronchogenic (3) · Genital Diseases, Male (3) · Genital Neoplasms, Male (3) · Liver Diseases (3)
Radiosurgery (4) · Cisplatin (1) · Drug Therapy (1) · Fluorouracil (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · Irinotecan (1) · Oxaliplatin (1) · Pancreatectomy (1) · Platinum (1) · Radiotherapy (1) · Surgical Procedures, Operative (1) · anlotinib (1) · apatinib (1)
Galera Therapeutics, Inc. (2) · Nanfang Hospital, Southern Medical University (2) · Consorci Sanitari de Terrassa (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Fudan University (1) · Fujian Cancer Hospital (1) · Fundacao Champalimaud (1) · Institut du Cancer de Montpellier - Val d'Aurelle (1) · Instituto de Investigación Sanitaria Aragón (1) · Medical University of Silesia (1) · Peking University First Hospital (1) · Robert Förster (1) · Shanghai Chest Hospital (1) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1)
China (7) · France (3) · Spain (3) · Canada (2) · United States (2) · Belgium (1) · Italy (1) · Poland (1) · Portugal (1) · United Kingdom (1)
Carlo Greco, M.D. (1) · Chen Jinzhang (1) · Christina Schroeder, MD (1) · Eugene P Kennedy, MD (1) · Gert De Meerleer, MD, PhD (1) · Jon Gadea Quinteiro, Principal investigator (1) · Manuel Galdeano-Rubio, MD (1) · Pierre Boisselier (1) · Xianshu Gao, MD,PhD (1)
PMID 34145168, PMID 22560555, PMID 26095785, PMID 26484629, PMID 26582738, PMID 26951040, PMID 38039992, PMID 38264869, PMID 40591115, PMID 41521299